2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Manish A. Shah, MD, discusses biomarkers of response to immunotherapy gastric/gastroesophageal cancer.
Manish A. Shah, MD, Bartlett Family Associate Professor Gastrointestinal Oncology and associate professor of medicine at Weill Cornell Medical College, Cornell University, and associate attending physician at NewYork-Presbyterian Hospital, discusses biomarkers of response to immunotherapy in gastric/gastroesophageal junction (GEJ) cancer.
Mismatch repair deficiency (dMMR) status can inform whether a patient is likely to respond to immunotherapy, explains Shah.
Combined positive score (CPS) also serves as a marker of response to immunotherapy, says Shah.
CPS may indicate which patients will benefit from immunotherapy in the third-line setting, concludes Shah.